Alysaa Phyars, DPM
Foot & Ankle Surgery · Albany, NYNPI 1952743262
Payments from drug & device makers
Across 135 payments — averaging $29.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Musculoskeletal Transplant Foundation Inc.$2K
- Novo Nordisk$509
- Abbott$450
- Organogenesis Inc.$308
- Smith+Nephew$288
- Nevro Corp.$112
- plus $739 from 17 others
What the payments were for
- Travel & lodging$1,50538%
- Food & beverage$2,43162%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Musculoskeletal Transplant Foundation Inc. | 8 | $1,529 |
| Novo Nordisk | 36 | $509 |
| Abbott | 22 | $450 |
| Organogenesis Inc. | 13 | $308 |
| Smith+Nephew | 15 | $288 |
| Nevro Corp. | 4 | $112 |
| Averitas Pharma Inc. | 4 | $102 |
| IBSA Pharma Inc. | 5 | $86 |
| Advanced Oxygen Therapy Inc. | 4 | $79 |
| Amgen | 4 | $69 |
| Bayer | 4 | $62 |
| Melinta Therapeutics, LLC | 2 | $59 |
| Paratek Pharmaceuticals, Inc. | 1 | $34 |
| Amryt Pharma Holdings Ltd | 2 | $34 |
| AbbVie | 1 | $33 |
| GRT US Holding, Inc. | 2 | $30 |
| Sanofi-aventis U.S. LLC | 1 | $28 |
| BD | 2 | $27 |
| Misonix Inc | 1 | $23 |
| Globus Medical | 1 | $21 |
| Kerecis Limited | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $14 |
How this compares
$3,936 in reported general payments places this provider in the 65th percentile of 652 foot & ankle surgery providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ammonium Lactate | 79 | $1,662 |
| Pregabalin | 72 | $1,573 |
| Diclofenac Sodium | 21 | $455 |
| Ciclopirox | 18 | $336 |
| Gabapentin | 31 | $261 |
| Terbinafine Hcl | 35 | $242 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 20 | $197 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 11 | $129 |
| Cephalexin | 12 | $83 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Albany
- James McWilliamHarrison$4.7M
- Jonathan DelandNew York$4.1M
- George Vitole Roy$2.5M
- Constantine DemetracopoulosNew York$888K
- Anne JohnsonNew York$815K
- Scott EllisNew York$644K
- John KennedyNew York$613K
- Michael KellerKingston$532K
- Judith BaumhauerRochester$365K
- Edward AzarBrooklyn$224K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.